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http://dx.doi.org/10.1016/j.jmii.2012Background: The majority of nosocomial infections in Taiwan hospitals are caused by drug-
resistant Gram-negative bacteria (GNB), including Pseudomonas aeruginosa, Acinetobacter
baumannii, and various species of Enterobacteriaceae. Carbapenems are important agents
for treating infections caused by these GNB. Recently, doripenem was approved for use in
Taiwan in August 2009. However, data on its in vitro activity against nosocomial GNB isolated
from Taiwan remain limited. The study was designed to look into this clinical issue.
Methods: A total of 400 nonduplicated nosocomial blood isolates isolated in 2009, inclusive of
P. aeruginosa (n Z 100), A. baumannii (n Z 100), and Enterobacteriaceae (n Z 200), were
randomly selected from the bacterial bank preserved at National Taiwan University Hospital.
Susceptibilities of these 400 isolates to various antibiotics, including doripenem, imipenem,
meropenem, ceftazidime, amikacin, ciprofloxacin, colistin, and tigecycline were determined
by using Etest.
Results: Doripenem demonstrated similar in vitro activity to imipenem and meropenem
against P. aeruginosa (87%, vs. 85% and 89%), A. baumannii (56%, vs. 60% and 60%), and Enter-
obacteriaceae (100%, vs. 98.5% and 99.5%). The prevalence of carbapenem-resistant (any one
of three tested carbapenems) P. aeruginosa, A. baumannii, and Enterobacteriaceae isolates
was 15%, 44%, and 0.5%, respectively.
Conclusions: Doripenem was as effective as imipenem and meropenem in our study. However,
there was a significant proportion of carbapenem resistance among the tested isolates. Hence,
longitudinal surveillance is necessary to monitor the resistance trend.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, No. 7,
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Table 1 Minimal inhibitory concentrations (MICs) of and susceptibilities to 8 antimicrobial agents in clinical isolates of P.
aeruginosa and A. baumannii
Antimicrobial agent MIC (mg/mL) and susceptibility (%S)
P. aeruginosa (n Z 100) A. baumannii(n Z 100)
Range MIC50 MIC90 %S
a Range MIC50 MIC90 %S
b
Ceftazidime 0.5e>256 1.5 16 87 1e>256 4 >256 60
Doripenem 0.064e>32 0.25 6 87 0.064e>32 0.38 >32 56
Imipenem 0.125e>32 1 24 85 0.125e>32 0.25 >32 60
Meropenem 0.064e>32 0.25 6 89 0.125e>32 0.5 >32 60
Amikacin 1e256 3 8 98 1e>256 6 >256 60
Ciprofloxacin 0.047e>32 0.094 1 90 0.047e>32 0.25 >32 57
Colistin 0.125e4 1 2 95 0.047e0.5 0.25 0.38 100
Tigecycline 1.5e96 12 24 0.094e12 0.5 3 84
a The susceptible breakpoints were: ceftazidime, 8 mg/mL; doripenem, 2 mg/mL; imipenem, 4 mg/mL; meropenem, 4 mg/mL;
amikacin, 16 mg/mL; ciprofloxacin, 1 mg/mL; colistin, 2 mg/mL.
b The susceptible breakpoints were: ceftazidime, 8 mg/mL; doripenem, 1 mg/mL; imipenem, 4 mg/mL; meropenem, 4 mg/mL;
amikacin, 16 mg/mL; ciprofloxacin, 1 mg/mL; colistin, 2 mg/mL; tigecycline, 2 mg/mL.
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8,9. It also has limited ability in the selection
6,10,11The majority of nosocomial infections in Taiwan hospitals
are caused by Gram-negative bacteria, including Pseudo-
monas aeruginosa, Acinetobacter baumannii, and various
species of Enterobacteriaceae.1 Among these Gram-
negative bacteria causing nosocomial infections, resis-
tance to b-lactam and other antimicrobial agents has
increased.1 Carbapenems have become one of the most
important agents for treating infections caused by these
multidrug resistance Gram-negative bacteria.2
Doripenem was approved use in Taiwan in August 2009.
Before that, imipenem/cilastatin and meropenem were the
only two antipseudomonal carbapenems available in
Taiwan.
Studies in other countries have demonstrated doripenem
to have similar in vitro activity to meropenem against
a wide range of Gram-negative pathogens and to imipenem
against Gram-positive pathogens.3,4
Doripenem has also been shown to have good activities
against extended-spectrum b-lactamase (ESBL) and
AmpC producing Enterobacteriaceae5e7 as well as toTable 2 Minimal inhibitory concentrations (MICs) of and susc
Enterobacteriaceae
Antimicrobial agent MIC (mg/m
Enterobacteriaceae (n Z 200) Esc
Range MIC50 MIC90 %S
a Range
Ceftazidime <0.016e>256 0.19 32 80 0.064e
Doripenem 0.004e0.75 0.032 0.094 100 0.012e
Imipenem 0.032e4 0.38 0.19 98.5 0.094e
Meropenem 0.004e1.5 0.032 0.094 99.5 0.012e
Amikacin 0.032e64 2 3 98.5 1e64
Ciprofloxacin 0.004e>32 0.032 16 86 0.006e
Colistin 0.125e>256 0.38 12 89 0.125e
Tigecycline 0.094e32 0.5 1.5 97.5 0.094e
a The susceptible breakpoints were: ceftazidime, 4 mg/mL; doripe
amikacin, 16 mg/mL; ciprofloxacin, 1 mg/mL; colistin, 2 mg/mL;of resistant strains in vitro. Doripenem has been
approved in the United States, European Union, and
Taiwan for the treatment of complicated urinary tract and
intra-abdominal infections.12,13 Doripenem has also been
approved for a wide range of infections in Japan14 and for
nosocomial pneumonia in the European Union.13 However,
the clinical experience of using doripenem to treat
infections caused by multidrug-resistant pathogens and
data on its in vitro activities against multidrug-resistant
pathogens remained limited in Taiwan.15
The study was designed to compare the in vitro activi-
ties of doripenem and other antimicrobial agents including
imipenem and meropenem, against drug-resistant Gram-
negative pathogens isolated in a medical center in Taiwan.
Materials and methods
Bacterial isolates
A total of 400 nonduplicate nosocomial blood isolates iso-
lated in 2009, including P. aeruginosa (n Z 100), A.eptibilities to 8 antimicrobial agents in clinical isolates of
L) and susceptibility (%S)
herichia coli (n Z 81) Klebsiella pneumoniae (n Z 57)
MIC50 MIC90 %S
a Range MIC50 MIC90 %S
a
>256 0.19 16 76.5 0.064e>256 0.19 0.75 91.2
0.25 0.023 0.047 100 0.023e0.38 0.032 0.047 100
1 0.19 0.25 100 0.094e4 0.19 0.25 98.2
0.19 0.023 0.094 100 0.016e1.5 0.023 0.047 98.2
2 4 97.5 1e48 2 2 98.2
>32 0.19 >32 72.8 0.008e>32 0.032 0.5 93
0.38 0.125 0.38 100 0.125e1 0.5 0.75 100
1.5 0.25 0.5 100 0.125e6 0.75 1.5 94.7
nem, 1 mg/mL; imipenem, 1 mg/mL; meropenem, 1 mg/mL;
tigecycline, 2 mg/mL.
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Figure 1. Cumulative MIC distributions of doripenem, imi-
penem, and meropenem among (A) Pseudomonas aeruginosa,
(B) Acinetobacter baumannii, and (C) Enterobacteriaceae
isolates.
In vitro activity of doripenem against GNB 461baumannii (n Z 100) and Enterobacteriaceae (n Z 200),
were randomly selected from the bacterial bank preserved
at National Taiwan University Hospital. Nosocomial isolates
were defined as those isolated after 48 hours after admis-
sion. The 200 Enterobacteriaceae isolates consisted of 81
Escherichia coli, 57 Klebsiella pneumoniae, 34 Enter-
obacter cloacae, 12 Serratia marcescens, seven Proteus
mirabilis, four Citrobacter freundii, three Morganella
morgannii and two Citrobacter koseri. These isolates were
reidentified using recommended traditional method prior to
susceptibility testing.16e18
Antimicrobial susceptibility test
In vitro susceptibilities to various antimicrobial agents of all
enrolled bacterial isolates were determined by minimum
inhibitory concentrations (MICs) using Etest (AB bioMe´rieux,
Marcy-l’Etoile, France). The tested antibiotics included
doripenem, imipenem, meropenem, ciprofloxacin, cefta-
zidime, amikacin, colistin, and tigecycline. The method-
ology used for susceptibility testing was direct colony
suspension, according to the manufacturer’s instructions.
P. aeruginosa ATCC 27853 and Escherichia coli ATCC 25922
were used for quality control in each run of test.
The susceptibility test results of ceftazidime, imipenem,
meropenem, amikacin, ciprofloxacin, and colistin were
interpreted using the criteria provided by the Clinical and
Laboratory standards Institute (CLSI), 2010.19,20 For tige-
cycline, we applied the criteria suggested by the US Food
and Drug Administration (US-FDA) for Enterobacteriaceae
(susceptibility 2 mg/mL ) to A. baumannii.
The susceptibility of doripenem for Enterobacteriaceae
was also interpreted using the CLSI criteria.20 However,
CLSI dose not provide interpretive criteria on doripenem for
P. aeruginosa and A. baumannii, hence, the US-FDA criteria
were used (susceptibility 2 mg/mL for P. aeruginosa and
1 mg/mL for A. baumannii). In this study, carbapenem
resistance was defined as resistance to either doripenem,
imipenem, or meropenem.
Results
The MIC distributions of and susceptibilities to the eight
tested antimicrobial agents against the 400 isolates are
shown in Table 1 (P. aeruginosa and A. baumannii) and
Table 2 (Enterobacteriaceae). For the 100 isolates of
P. aeruginosa, the proportion of carbapenem resistance was
15%. Among the carbapenem-resistant P. aeruginosa, the
susceptibility rates of ceftazidime, amikacin, ciprofloxacin,
and colistin were 53.3%, 80%, 60%, and 93.3%, respectively.
For the 100 isolates of A. baumannii, the proportion of
carbapenem resistance was 44%. Among the carbapenem-
resistant A. baumannii, the susceptibility rates of ceftazi-
dime, amikacin, ciprofloxacin, tigecycline, and colistin
were 18.2%, 18.2%, 20.5%, 70.5%, and 100%, respectively.
Among the Enterobacteriaceae nonsusceptible to cef-
tazidime, the susceptibility rates of doripenem, imipenem,
meropenem, tigecycline, and colistin were 100%, 97.5%,
100%, 92.5%, and 95%, respectively (Table 2).
The cumulative MIC distributions of three tested carba-
penems for P. aeruginosa, A. baumannii andEnterobacteriaceae are plotted in Figs. 1. Fig. 1A and C
showed a similar trend of the MIC distributions of dor-
ipenem and meropenem against P. aeruginosa and Enter-
obacteriaceae, while the MIC distributions curve of
imipenem showed a rightward shift indicating a higher MIC
distribution. Fig. 1B shows the nearly overlapping MIC
distributions curves of doripenem, meropenem and imipe-
nem against A. baumannii (a similar MIC distribution).
Comparisons of the susceptibility rates and non-
susceptibility rates of P. aeruginosa, A. baumannii, and
Table 3 Comparison of doripenem and imipenem susceptibilities
Number of isolates Susceptible
to doripenema
Not susceptible
to doripenema
Kappa
Pseudomonas aeruginosa
Susceptible to imipenemb 83 1
Not susceptible to imipenemb 4 12 0.799
Acinetobacter baumannii
Susceptible to imipenemb 56 4
Not susceptible to imipenemb 0 40 0.918
Enterobacteriaceae
Susceptible to imipenemb 197 0
Not susceptible to imipenemb 3 0 Could not be calculated
a Based on the breakpoints approved by the US Food and Drug Administration (FDA) in April 2009.
b Based on CLSI M100-S20 interpretive criteria.
462 S.-X. Dong et al.Enterobacteriaceae between doripenem and imipenem are
shown in Table 3. The susceptibility rates and non-
susceptibility rates of P. aeruginosa, A. baumannii, and
Enterobacteriaceae between doripenem and imipenem
were similar. Comparisons of the susceptibility rates and
nonsusceptibility rates of P. aeruginosa, A. baumannii, and
Enterobacteriaceae between doripenem and meropenem
are shown in Table 4. The kappa values of these compari-
sons were 0.905, 0.918, and >0.999, respectively. The
susceptibility rates and non-susceptibility rates of P. aeru-
ginosa, A. baumannii, and Enterobacteriaceae between
doripenem and meropenem were also similar.Discussion
When an antimicrobial agent is launched and planned to
be used for treating infections in a region, it is important
to know first its in vitro activity against clinical relevant
pathogens in that region. Before our investigation, there
has only been one study in Taiwan, which reported the
susceptibility and in vitro activity of doripenem against
clinically important bacteria.15 Since the bacterial
isolates used in that study were collected in 2005,15
there might have been significant changes in drug resis-
tance during this time period. Therefore, we conductedTable 4 Comparison of doripenem and meropenem susceptibil
Number of isolates Susceptible
to doripenem
Pseudomonas aeruginosa
Susceptible to meropenemb 87
Not susceptible to meropenemb 0
Acinetobacter baumannii
Susceptible to meropenemb 56
Not susceptible to meropenemb 0
Enterobacteriaceae
Susceptible to meropenemb 200
Not susceptible to meropenemb 0
a Based on the breakpoints approved by the US Food and Drug Adm
b Based on CLSI M100-S20 interpretive criteria.the present study using more contemporary clinical
isolates.
The current study demonstrated that doripenem has
similar in vitro activity to imipenem and/or meropenem
against P. aeruginosa, A. baumannii, and various species of
Enterobacteriaceae. However, susceptibility to doripenem
in P. aeruginosa was slightly higher than imipenem (87% vs.
85%). In contrast, susceptibility rate of doripenem for A.
baumannii was slightly lower compared to imipenem and
meropenem (56% vs. 60% and 60%; Table 3 and Table 4).
This result was similar to prior studies conducted in the
United States and worldwide.21,22 Doripenem also had
a slightly higher susceptibility rate for Enterobacteriaceae
(100% vs. 98.5% & 99.5%) compared to imipenem and mer-
openem (Table 3 and Table 4).
For the susceptibility of Enterobacteriaceae to ceftazi-
dime, we applied the new 2010 CLSI criteria. Therefore, we
did not test for the presence of ESBL producer.19 Among the
Enterobacteriaceae isolates not susceptible to ceftazidime,
the susceptibilities to doripenem, imipenem, meropenem,
tigecycline and colistin were still high but the susceptibility
rate of ciprofloxacin was only 65%.
This study revealed similar rates of susceptibility
to doripenem in P. aeruginosa, A. baumannii, and Enter-
obacteriaceae compared to previous studies conducted
indifferent countries (87%vs. 77.2e100%,56%vs.41.8e75.8%,ities
a
Not susceptible
to doripenema
Kappa
2
11 0.905
4
40 0.918
0
0 >0.999
inistration (FDA) in April 2009.
In vitro activity of doripenem against GNB 463and 100% vs. 98.5e99.5%, respectively).8,21e25 Similar trends
were also seen in other tested antibiotics.21e29
Compared to the study conducted by Jean et al, the only
study investigated the susceptibilities to doripenem in
Taiwan before our study,15 we found that the MIC90s of
doripenem and meropenem in P. aeruginosa and A. bau-
mannii were both increased (6 mg/mL and 6 mg/mL vs. 1 mg/
mL and 4 mg/mL, >32 mg/mL and >32 mg/mL vs. 16 mg/mL
and 16 mg/mL, respectively). We could not compare the
differences in susceptibility rates, because Jean et al did
not report these rates in their study. The increase in MIC90
values might be due to different source of enrolled bacteria
(single center vs. multicenter); however, it might be also
due to a real increase of drug resistance during this 4-year
interval. Increased prevalence of carbapenem resistance
among clinical isolates of A. baumannii has been noted
recently worldwide.30 It is necessary to conduct a longitu-
dinal study for continuous monitoring of carbapenem
resistance.
The MIC90 values of carbapenems in Enterobacteriaceae
in the study did not increase in comparison to that of Jean
et al (0.047 mg/mL vs. 0.06e0.12 mg/mL). This might imply
that carbapenem resistance among Enterobacteriaceae
remains low and stable in Taiwan, unlike some reports
indicating rapid increase of carbapenem resistance in
Enterobacteriaceae from Europe and USA.31
In conclusion, our study revealed that doripenem exer-
ted similar in vitro activity against the tested bacteria
compared to imipenem and meropenem. With comparison
to the prior study conducted in Taiwan in 2005, the MIC90
values of doripenem, imipenem, and meropenem have
increased in P. aeruginosa and A. baumannii. Longitudinal
surveillance to monitor carbapenem resistance trend is
needed.Acknowledgments
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